Odluka o izmjenama i dopunama Odluke o utvrđivanju Osnovne liste lijekova Hrvatskog zavoda za zdravstveno osiguranje
NN 6/2022 (14.1.2022.), Odluka o izmjenama i dopunama Odluke o utvrđivanju Osnovne liste lijekova Hrvatskog zavoda za zdravstveno osiguranje
Hrvatski zavod za zdravstveno osiguranje
57
Na osnovi članka 20. stavka 7. Zakona o obveznom zdravstvenom osiguranju (»Narodne novine«, broj 80/13., 137/13. i 98/19.) i članka 26. točke 10. Statuta Hrvatskog zavoda za zdravstveno osiguranje (»Narodne novine«, broj 18/09., 33/10., 08/11., 18/13., 1/14., 83/15. i 108/21.) Upravno vijeće Hrvatskog zavoda za zdravstveno osiguranje na 43. sjednici održanoj 11. siječnja 2022. godine, uz prethodno pribavljeno mišljenje Hrvatske liječničke komore, donijelo je
ODLUKU
O IZMJENAMA I DOPUNAMA ODLUKE O UTVRĐIVANJU OSNOVNE LISTE LIJEKOVA HRVATSKOG ZAVODA ZA ZDRAVSTVENO OSIGURANJE
Članak 1.
U Odluci o utvrđivanju Osnovne liste lijekova Hrvatskog zavoda za zdravstveno osiguranje (»Narodne novine«, broj 135/21.), u Osnovnoj listi lijekova iz članka 2. stavka 5. pod šiframa anatomsko-terapijsko-kemijske (ATK) klasifikacije lijekova Svjetske zdravstvene organizacije mijenjaju se sljedeći podaci:
»
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena za DDD | Cijena za DDD (s PDV-om) | Način primjene | Nositelj odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena jed. oblika | Cijena jed. oblika (s PDV-om) | Cijena orig. pakiranja | Cijena orig. pakiranja (s PDV-om) | R/RS |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. | 15. | 16. |
| B02BB01 071 | DS | fibrinogen | 5 g | 14.690,00 | 15.424,50 | P | Jana Pharm d.o.o. | Octapharma Pharmazeutika Produktionsges .m.b.H., Octapharma AB | Fibryga | praš. i otap. za otop. za inj./inf., stak. boč. 1x1 g | 2.938,00 | 3.084,90 | 2.938,00 | 3.084,90 | |
| B02BD04 095 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x250 i.j. | 891,19 | 935,75 | 891,19 | 935,75 | ||||
| B02BD04 096 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x500 i.j. | 1.782,38 | 1.871,50 | 1.782,38 | 1.871,50 | ||||
| B02BD04 097 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x1.000 i.j. | 3.564,76 | 3.743,00 | 3.564,76 | 3.743,00 | ||||
| B02BD04 098 | DS | rekombinantni čimbenik IX (nonakog alfa)NB205 | P | Pfizer Europe MA EEIG | Wyeth Farma S.A. | BeneFIX | praš. i otap. za otop. za inj., boč. stakl. 1x2.000 i.j. | 7.129,52 | 7.486,00 | 7.129,52 | 7.486,00 | ||||
| B05AA01 064 | DS | ljudski albumin 20%NB502 | P | Jana Pharm d.o.o. | Octapharma | Albunorm 20% (non HR) | otop. za inf., boč. stakl. 1x100 ml | 408,59 | 429,02 | 408,59 | 429,02 | ||||
| C01CA07 061 | DS | dobutamin | 0,5 g | 58,00 | 60,90 | P | Panpharma | Panpharma GmbH | Dobutamin Panpharma | konc. za otop. za inf., boč. stakl. 10x250 mg/20 ml | 29,00 | 30,45 | 290,00 | 304,50 | |
| D06AX09 461 | mupirocin | L | GlaxoSmithKline Trading Services Limited | Glaxo Operations UK Limited, GlaxoSmithKline Pharmaceuticals S.A. | Bactroban | mast 1x15 g (20 mg/g) | 26,13 | 27,44 | 26,13 | 27,44 | R | ||||
| H05AA02 001 | RL | teriparatid | 20 mcg | 54,67 | 57,40 | P | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Pharma B.V. | Teriparatid Pliva | otop. za inj., brizg. napunj. 1x600 mcg/2,4 ml (250 mcg/ml) | 1.640,11 | 1.722,12 | 1.640,11 | 1.722,12 | RSRH07 |
| J01CR02 171 | amoksicilin + klavulanska kiselina | 1.5 g | 4,04 | 4,24 | O | GlaxoSmithKline Trading Services Limited | SmithKline Beecham Pharmaceuticals, Glaxo Wellcome Production | Augmentin | tbl. film obl. 14x1 g (875 mg +125 mg) | 2,36 | 2,48 | 33,00 | 34,65 | RRJ04 | |
| J01CR02 273 | amoksicilin + klavulanska kiselina | 1.5 g | 6,01 | 6,31 | O | GlaxoSmithKline Trading Services Limited | SmithKline Beecham Pharmaceuticals, Glaxo Wellcome Production | Augmentin | susp. 70 ml(400 mg +57 mg)/5 ml | 22,45 | 23,57 | 22,45 | 23,57 | RRJ04 | |
| J01CR05 041 | DS | piperacilin + tazobaktamNJ101 | 14 g | 216,38 | 227,20 | P | Sandoz d.o.o. | Sandoz | Piperacilin/tazobaktam Sandoz | praš. za otop. za inf., boč. 10x(4,0 g+0,5 g)/100ml | 61,82 | 64,91 | 618,23 | 649,14 | |
| J01MA12 021 | DS | levofloksacinNJ105 | 0,5 g | 132,53 | 139,16 | P | Sandoz d.o.o. | Lek Pharmaceuticals d.d. | Levofloksacin Sandoz | otop. za inf., vreć. 1x100 ml (5 mg/ml) | 132,53 | 139,16 | 132,53 | 139,16 | |
| J05AB06 071 | KS | ganciklovir | 0,5 g | 225,94 | 237,24 | P | Cheplapharm Arzneimittel GmbH | Cheplapharm Arzneimittel GmbH, Prestige Promotion Verkaufsförderung & Werbeservice GmbH | Cymevene | boč. 1x500 mg/10 ml | 225,94 | 237,24 | 225,94 | 237,24 | |
| J05AH01 771 | DS | zanamivirNJ506 | 20 mg | 22,99 | 24,14 | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Limited | Relenza | praš. za inhal. 20x5 mg (5 rotadisk blist. po 4 doze +diskhaler) | 5,75 | 6,03 | 114,93 | 120,68 | |
| J05AP54 161 | DS | elbasvir + grazoprevirNJ711 | O | Merck Sharp & Dohme B.V. | Schering-Plough Labo N.V. | Zepatier | tbl. film obl. 28x(50 mg+100 mg) | 2.488,60 | 2.613,03 | 69.680,89 | 73.164,93 | ||||
| J05AP54 162 | DS | elbasvir + grazoprevirNJ711 | O | Merck Sharp & Dohme B.V. | Schering-Plough Labo N.V. | Zepatier | tbl. film obl. 28x(50 mg+100 mg) | 2.488,60 | 2.613,03 | 69.680,89 | 73.164,93 | ||||
| J06BA01 061 | imunoglobulin, ljudskiNJ708 | P | Jana Pharm d.o.o. | Octapharma AB | Gammanorm | otop. za inj., boč. 1x10 ml (165 mg/ml) | 727,77 | 764,16 | 727,77 | 764,16 | RSRJ53 | ||||
| J06BD01 051 | DS | palivizumabNJ605 | P | ||||||||||||
| J06BD01 084 | DS | palivizumabNJ605 | P | AstraZeneca AB | AbbVie S.r.l. | Synagis | otop. za inj., boč. stakl. 1x1 ml (100 mg/mL) | 6.252,88 | 6.565,52 | 6.252,88 | 6.565,52 | ||||
| J07BC01 074 | DS | cjepivo protiv hepatitisa B | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Engerix -B dosis adulta | 1x20 mcg/1 ml susp. za inj. u napunj. štrc. | 78,87 | 82,81 | 78,87 | 82,81 | ||||
| J07BC01 075 | DS | cjepivo protiv hepatitisa B | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Engerix -B dosis pediatrica | 1x10 mcg/0,5 ml susp. za inj. u napunj. štrc. | 48,00 | 50,40 | 48,00 | 50,40 | ||||
| J07BD52 061 | PR | cjepivo protiv morbila-parotitisa-rubele (MO-PA-RU) | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Priorix | cjepivo kombinirano, liof., boč. 1x1 doza +štrc. napunj. s 0,5 ml vode za injekcije+2 igle sa zaštitom | 66,32 | 69,64 | 66,32 | 69,64 | ||||
| J07CA06 071 | PR | cjepivo protiv difterije, tetanusa-DT, pertusisa-(acelularno), poliomijelitisa-IPV (inaktivirano), adsorbirano i Haemophilus influenzae tip b (konjugirano)NJ707 | P | GlaxoSmithKline Biologicals S.A. | GlaxoSmithKline Biologicals S.A. | Infanrix-IPV+Hib | štrc. stakl. 1x0,5 ml +1 stakl.boč. s praškom +2 igle sa zaštitom, susp. | 141,29 | 148,35 | 141,29 | 148,35 | ||||
| L01EA01 101 | DS | imatinibNL115 | 400 mg | 218,28 | 229,19 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivatinib | tbl. film obl. 60x100 mg | 54,57 | 57,30 | 3.274,20 | 3.437,91 | |
| L01EA01 102 | DS | imatinibNL115 | 400 mg | 209,51 | 219,99 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Plivatinib | tbl. film obl. 30x400 mg | 209,51 | 219,99 | 6.285,30 | 6.599,57 | |
| L01EA01 121 | DS | imatinibNL458 | 400 mg | 171,23 | 179,80 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d., Salutas Pharma GmbH | Imatinib Sandoz | tbl. film obl. 60x100 mg | 42,81 | 44,95 | 2.568,51 | 2.696,94 | |
| L01EA01 122 | DS | imatinibNL458 | 400 mg | 169,86 | 178,35 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d., Salutas Pharma GmbH | Imatinib Sandoz | tbl. film obl. 30x400 mg | 169,86 | 178,35 | 5.095,71 | 5.350,50 | |
| L01EA01 135 | DS | imatinib NL115 | 400 mg | 218,28 | 229,19 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 60x100 mg | 54,57 | 57,30 | 3.274,20 | 3.437,91 | |
| L01EA01 136 | DS | imatinib NL115 | 400 mg | 222,05 | 233,16 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 90x100 mg | 55,51 | 58,29 | 4.996,20 | 5.246,01 | |
| L01EA01 137 | DS | imatinibNL115 | 400 mg | 209,51 | 219,99 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 30x400 mg | 209,51 | 219,99 | 6.285,30 | 6.599,57 | |
| L01EA01 138 | DS | imatinib NL115 | 400 mg | 204,52 | 214,75 | O | KRKA-FARMA d.o.o. | KRKA-FARMA d.o.o., Krka d.d. | Meaxin | tbl. film obl. 60x400 mg | 204,52 | 214,75 | 12.271,20 | 12.884,76 | |
| L01EA01 141 | DS | imatinibNL115 | 400 mg | 162,67 | 170,81 | O | Alkaloid-INT d.o.o. | Alkaloid - INT d.o.o. | Imatinib Alkaloid-INT | tbl. film obl. 60x100 mg | 40,67 | 42,70 | 2.440,08 | 2.562,08 | |
| L01EA01 142 | DS | imatinibNL115 | 400 mg | 161,36 | 169,43 | O | Alkaloid-INT d.o.o. | Alkaloid - INT d.o.o. | Imatinib Alkaloid-INT | tbl. film obl. 30x400 mg | 161,36 | 169,43 | 4.840,92 | 5.082,97 | |
| L01EA01 161 | DS | imatinibNL115 | 400 mg | 218,28 | 229,19 | O | Zentiva k.s. | Remedica Ltd., Pharmadox Healthcare Ltd. | Imakrebin | tbl. film obl. 60x100 mg | 54,57 | 57,30 | 3.274,20 | 3.437,91 | |
| L01EA01 162 | DS | imatinibNL115 | 400 mg | 209,51 | 219,99 | O | Zentiva k.s. | Remedica Ltd., Pharmadox Healthcare Ltd. | Imakrebin | tbl. film obl. 30x400 mg | 209,51 | 219,99 | 6.285,30 | 6.599,57 | |
| L01EA01 173 | DS | imatinibNL115 | 400 mg | 209,51 | 219,99 | O | Novartis Europharm Limited Irska | Novartis Pharma | Glivec | tbl. film obl. 30x400 mg | 209,51 | 219,99 | 6.285,30 | 6.599,57 | |
| L01EA01 193 | DS | imatinibNL115 | 400 mg | 190,26 | 199,77 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Imatinib Accord | tbl. film obl. 60x100 mg | 47,57 | 49,94 | 2.853,90 | 2.996,60 | |
| L01EA01 194 | DS | imatinibNL115 | 400 mg | 188,73 | 198,17 | O | Accord Healthcare S.L.U. | Accord Healthcare Limited | Imatinib Accord | tbl. film obl. 30x400 mg | 188,73 | 198,17 | 5.661,90 | 5.945,00 | |
| L01EA02 161 | DS | dasatinibNL119 | 100 mg | 1.002,50 | 1.052,62 | O | Bristol-Myers Squibb Pharma EEIG | Bristol-Myers Squibb | Sprycel | tbl. film obl. 60x20 mg | 200,50 | 210,53 | 12.030,00 | 12.631,50 | |
| L01EA02 163 | DS | dasatinibNL119 | 100 mg | 603,42 | 633,59 | O | Bristol-Myers Squibb Pharma EEIG | Bristol-Myers Squibb | Sprycel | tbl. film obl. 30x100 mg | 603,42 | 633,59 | 18.102,60 | 19.007,73 | |
| L01EA02 171 | DS | dasatinibNL119 | 100 mg | 701,75 | 736,84 | O | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Dasatinib Zentiva | tbl. film obl. 60x20 mg | 140,35 | 147,37 | 8.421,00 | 8.842,05 | |
| L01EA02 172 | DS | dasatinibNL119 | 100 mg | 422,39 | 443,51 | O | Zentiva k.s. | Synthon Hispania S.L., Synthon BV | Dasatinib Zentiva | tbl. film obl. 30x100 mg | 422,39 | 443,51 | 12.671,82 | 13.305,41 | |
| L01EA03 171 | DS | nilotinibNL121 | 600 mg | 655,85 | 688,64 | O | Novartis Europharm Limited Irska | Novartis Pharma Stein AG | Tasigna | caps. tvrda 112x200 mg | 218,62 | 229,55 | 24.485,07 | 25.709,32 | |
| L01EA04 161 | DS | bosutinibNL119 | 400 mg | 704,91 | 740,16 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Bosulif | tbl. film obl. 28x100 mg | 176,23 | 185,04 | 4.934,40 | 5.181,12 | |
| L01EA04 162 | DS | bosutinibNL119 | 400 mg | 706,20 | 741,51 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Bosulif | tbl. film obl. 28x500 mg | 882,75 | 926,89 | 24.717,00 | 25.952,85 | |
| L01EA05 161 | DS | ponatinibNL526 | 45 mg | 2.093,90 | 2.198,60 | O | Incyte Biosciences Distribution B.V. | Incyte Biosciences Distribution B.V. | Iclusig | tbl. film obl. 60x15 mg | 697,97 | 732,87 | 41.878,00 | 43.971,90 | |
| L01EA05 162 | DS | ponatinibNL526 | 45 mg | 1.350,29 | 1.417,80 | O | Incyte Biosciences Distribution B.V. | Incyte Biosciences Distribution B.V. | Iclusig | tbl. film obl. 30x45 mg | 1.350,29 | 1.417,80 | 40.508,60 | 42.534,03 | |
| L01EB01 101 | DS | gefitinibNL419 | 250 mg | 248,34 | 260,76 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o. | Gefitinib Pliva | tbl. film obl. 30x250 mg | 248,34 | 260,76 | 7.450,20 | 7.822,71 | |
| L01EB01 141 | DS | gefitinibNL419 | 250 mg | 235,92 | 247,72 | O | Alkaloid-INT d.o.o. | Alkaloid - INT d.o.o. | Phrompo | tbl. film obl. 30x250 mg | 235,92 | 247,72 | 7.077,69 | 7.431,57 | |
| L01EB01 171 | DS | gefitinibNL419 | 250 mg | 306,60 | 321,93 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Gefitinib Alpha-Medical | tbl. film obl. 30x250 mg | 306,60 | 321,93 | 9.198,00 | 9.657,90 | |
| L01EB01 181 | DS | gefitinibNL419 | 250 mg | 306,60 | 321,93 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Gefitinib Sandoz | tbl. film obl. 30x250 mg | 306,60 | 321,93 | 9.198,00 | 9.657,90 | |
| L01EB01 191 | DS | gefitinibNL419 | 250 mg | 275,94 | 289,74 | O | Zentiva k.s. | Pharmadox Healthcare Limited, S.C Labormed - Pharma SA | Gefitinib Zentiva | tbl. film obl. 30x250 mg | 275,94 | 289,74 | 8.278,20 | 8.692,11 | |
| L01EB02 161 | DS | erlotinibNL116 | 150 mg | 243,05 | 255,20 | O | Roche Registration GmbH | Roche | Tarceva | tbl. film obl. 30x150 mg | 243,05 | 255,20 | 7.291,46 | 7.656,03 | |
| L01EB02 162 | DS | erlotinibNL116 | 150 mg | 243,05 | 255,20 | O | Zentiva k.s. | Remedica Ltd. | Varlota | tbl. film obl. 30x150 mg | 243,05 | 255,20 | 7.291,46 | 7.656,03 | |
| L01EB02 163 | DS | erlotinibNL116 | 150 mg | 243,05 | 255,20 | O | Remedica Ltd. | Remedica Ltd. | Erlotinib Remedica | tbl. film obl. 30x150 mg | 243,05 | 255,20 | 7.291,46 | 7.656,03 | |
| L01EB02 164 | DS | erlotinibNL116 | 150 mg | 243,05 | 255,20 | O | PharmaS d.o.o. | Remedica Ltd. | Erlotinib PharmaS | tbl. film obl. 30x150 mg | 243,05 | 255,20 | 7.291,46 | 7.656,03 | |
| L01EB02 165 | DS | erlotinibNL116 | 150 mg | 243,05 | 255,20 | O | ACTAVIS GROUP PTC ehf. | S.C. Sindan-Pharma S.R.L. | Erlotinib Actavis | tbl. film obl. 30x150 mg | 243,05 | 255,20 | 7.291,46 | 7.656,03 | |
| L01EB02 166 | DS | erlotinibNL116 | 150 mg | 218,74 | 229,68 | O | Sandoz d.o.o. | Lek Pharmaceuticals d.d., Remedica Ltd. | Erlotinib Sandoz | tbl. film obl. 30x150 mg | 218,74 | 229,68 | 6.562,31 | 6.890,43 | |
| L01EB02 167 | DS | erlotinibNL116 | 150 mg | 196,87 | 206,71 | O | Mylan S.A.S | Remedica Ltd. | Erlotinib Mylan | tbl. film obl. 30x150 mg | 196,87 | 206,71 | 5.906,08 | 6.201,38 | |
| L01EB02 168 | DS | erlotinibNL116 | 150 mg | 187,03 | 196,38 | O | KRKA-FARMA d.o.o. | Krka d.d. | Erlotinib Krka | tbl. film obl. 30x150 mg | 187,03 | 196,38 | 5.610,78 | 5.891,32 | |
| L01EB03 161 | DS | afatinibNL419 | 40 mg | 1.032,76 | 1.084,40 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Giotrif | tbl. film obl. 28x20 mg | 516,38 | 542,20 | 14.458,64 | 15.181,57 | |
| L01EB03 162 | DS | afatinibNL419 | 40 mg | 688,51 | 722,93 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Giotrif | tbl. film obl. 28x30 mg | 516,38 | 542,20 | 14.458,64 | 15.181,57 | |
| L01EB03 163 | DS | afatinibNL419 | 40 mg | 516,38 | 542,20 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim | Giotrif | tbl. film obl. 28x40 mg | 516,38 | 542,20 | 14.458,64 | 15.181,57 | |
| L01EB04 161 | KS | osimertinibNL473 | 80 mg | 3.037,70 | 3.189,59 | O | AstraZeneca AB | AstraZeneca AB | Tagrisso | tbl. film obl. 28x40 mg | 1.518,85 | 1.594,79 | 42.527,80 | 44.654,19 | |
| L01EB04 162 | KS | osimertinibNL473 | 80 mg | 1.518,85 | 1.594,79 | O | AstraZeneca AB | AstraZeneca AB | Tagrisso | tbl. film obl. 28x80 mg | 1.518,85 | 1.594,79 | 42.527,80 | 44.654,19 | |
| L01EC01 061 | KS | vemurafenibNL422 | 1920 mg | 1.716,24 | 1.802,05 | O | Roche Registration GmbH | Roche Pharma AG | Zelboraf | tbl. film obl. 56x240 mg | 214,53 | 225,26 | 12.013,68 | 12.614,36 | |
| L01EC02 162 | KS | dabrafenibNL422 | 300 mg | 1.576,26 | 1.655,07 | O | Novartis Europharm Limited Irska | Glaxo Wellcome S.A. | Tafinlar | caps. tvrda 120x50 mg | 262,71 | 275,85 | 31.525,20 | 33.101,46 | |
| L01EC02 163 | KS | dabrafenibNL422 | 300 mg | 1.584,39 | 1.663,61 | O | Novartis Europharm Limited Irska | Glaxo Wellcome S.A. | Tafinlar | caps. tvrda 120x75 mg | 396,10 | 415,90 | 47.531,60 | 49.908,18 | |
| L01ED01 161 | DS | krizotinibNL444 | 500 mg | 1.366,22 | 1.434,53 | O | Pfizer Europe MA EEIG | Pfizer | Xalkori | caps. tvrda 60x200 mg | 546,49 | 573,81 | 32.789,29 | 34.428,75 | |
| L01ED01 162 | DS | krizotinibNL444 | 500 mg | 1.092,98 | 1.147,63 | O | Pfizer Europe MA EEIG | Pfizer | Xalkori | caps. tvrda 60x250 mg | 546,49 | 573,81 | 32.789,29 | 34.428,75 | |
| L01ED03 161 | DS | alektinibNL474 | 1200 mg | 1.418,75 | 1.489,68 | O | Roche Registration GmbH | Roche Pharma AG | Alecensa | caps. tvrda 224x150 mg | 177,34 | 186,21 | 39.724,91 | 41.711,16 | |
| L01ED04 071 | DS | brigatinibNL501 | 180 mg | 1.377,96 | 1.446,86 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. 28x30 mg | 229,66 | 241,14 | 6.430,48 | 6.752,00 | |
| L01ED04 072 | DS | brigatinibNL501 | 180 mg | 1.356,29 | 1.424,11 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. 28x90 mg | 678,15 | 712,05 | 18.988,11 | 19.937,52 | |
| L01ED04 073 | DS | brigatinibNL501 | 180 mg | 1.128,97 | 1.185,42 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. 28x180 mg | 1.128,97 | 1.185,42 | 31.611,16 | 33.191,72 | |
| L01ED04 074 | DS | brigatinibNL501 | 180 mg | 1.290,25 | 1.354,76 | O | Takeda Pharma A/S | Takeda Austria GmbH, Penn Pharmaceutical Services Limited | Alunbrig | tbl. film obl. (7x90 mg+21x180 mg) | 1.128,97 | 1.185,42 | 31.611,16 | 33.191,72 | |
| L01ED05 161 | DS | lorlatinibNL511 | 100 mg | 1.422,46 | 1.493,58 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Lorviqua | tbl. film obl. 90x25 mg | 355,62 | 373,40 | 32.005,35 | 33.605,62 | |
| L01ED05 162 | DS | lorlatinibNL511 | 100 mg | 1.423,27 | 1.494,43 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Lorviqua | tbl. film obl. 120x25 mg | 355,82 | 373,61 | 42.698,09 | 44.832,99 | |
| L01ED05 163 | DS | lorlatinibNL511 | 100 mg | 1.066,85 | 1.120,19 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Lorviqua | tbl. film obl. 30x100 mg | 1.066,85 | 1.120,19 | 32.005,35 | 33.605,62 | |
| L01EE01 161 | KS | trametinibNL422 | 2 mg | 1.108,47 | 1.163,89 | O | Novartis Europharm Limited Irska | Glaxo Wellcome, S.A., Novartis Pharmaceuticals UK Limited, Novartis Pharma GmbH | Mekinist | tbl. film obl. 30x0,5 mg | 277,12 | 290,97 | 8.313,50 | 8.729,18 | |
| L01EE01 162 | KS | trametinibNL422 | 2 mg | 1.099,61 | 1.154,59 | O | Novartis Europharm Limited Irska | Glaxo Wellcome, S.A., Novartis Pharmaceuticals UK Limited, Novartis Pharma GmbH | Mekinist | tbl. film obl. 30x2 mg | 1.099,61 | 1.154,59 | 32.988,30 | 34.637,72 | |
| L01EE02 161 | KS | kobimetinibNL422 | 45 mg | 1.362,64 | 1.430,77 | O | Roche Registration GmbH | Roche Pharma AG | Cotellic | tbl. film obl. 63x20 mg | 605,62 | 635,90 | 38.153,85 | 40.061,54 | |
| L01EF01 161 | DS | palbociklibNL478 | 94 mg | 1.482,60 | 1.556,73 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | caps. tvrda 21x75 mg | 1.182,92 | 1.242,07 | 24.841,39 | 26.083,46 | |
| L01EF01 162 | DS | palbociklibNL478 | 94 mg | 1.111,95 | 1.167,55 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | caps. tvrda 21x100 mg | 1.182,92 | 1.242,07 | 24.841,39 | 26.083,46 | |
| L01EF01 163 | DS | palbociklibNL478 | 94 mg | 889,56 | 934,04 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | caps. tvrda 21x125 mg | 1.182,92 | 1.242,07 | 24.841,39 | 26.083,46 | |
| L01EF01 164 | DS | palbociklibNL478 | 94 mg | 1.211,49 | 1.272,07 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | tbl. film obl. 21x75 mg | 966,62 | 1.014,95 | 20.298,95 | 21.313,90 | |
| L01EF01 165 | DS | palbociklibNL478 | 94 mg | 908,62 | 954,05 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | tbl. film obl. 21x100 mg | 966,62 | 1.014,95 | 20.298,95 | 21.313,90 | |
| L01EF01 166 | DS | palbociklibNL478 | 94 mg | 726,90 | 763,24 | O | Pfizer Europe MA EEIG | Pfizer Manufacturing Deutschland GmbH | Ibrance | tbl. film obl. 21x125 mg | 966,62 | 1.014,95 | 20.298,95 | 21.313,90 | |
| L01EF02 161 | DS | ribociklibNL479 | 450 mg | 805,95 | 846,25 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Kisqali | tbl. film obl. 63x200 mg | 358,20 | 376,11 | 22.566,60 | 23.694,93 | |
| L01EF03 171 | DS | abemaciklibNL498 | 300 mg | 1.988,31 | 2.087,73 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Verzenios | tbl. film obl. 28x50 mg | 331,39 | 347,95 | 9.278,78 | 9.742,72 | |
| L01EF03 172 | DS | abemaciklibNL498 | 300 mg | 994,16 | 1.043,86 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Verzenios | tbl. film obl. 28x100 mg | 331,39 | 347,95 | 9.278,78 | 9.742,72 | |
| L01EF03 173 | DS | abemaciklibNL498 | 300 mg | 662,77 | 695,91 | O | Eli Lilly Nederland B.V. | Lilly S.A. | Verzenios | tbl. film obl. 28x150 mg | 331,39 | 347,95 | 9.278,78 | 9.742,72 | |
| L01EG01 071 | DS | temsirolimusNL122 | 3.57 mg | 764,60 | 802,83 | P | Pfizer Europe MA EEIG | Wyeth | Torisel | konc. i otap. za inf. boč. stakl. 1x30 mg/1,2 ml+boč. stakl. 1x2,2 ml | 6.425,25 | 6.746,51 | 6.425,25 | 6.746,51 | |
| L01EG01 081 | DS | temsirolimusNL122 | 3.57 mg | 535,22 | 561,99 | P | Accord Healthcare Polska Sp. z o.o. | Accord Healthcare Polska Sp. z o.o., Accord Healthcare B.V. | Temsirolimus Accord | konc. i otap. za otop. za inf. boč. stakl. 30 mg, 1 boč. s konc. i 1 boč. s otap. | 4.497,68 | 4.722,56 | 4.497,68 | 4.722,56 | |
| L01EG02 101 | DS | everolimusNL420 | 10 mg | 568,49 | 596,92 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Everolimus Pliva | tbl. 30x5 mg | 284,25 | 298,46 | 8.527,39 | 8.953,76 | |
| L01EG02 102 | DS | everolimusNL420 | 10 mg | 388,32 | 407,73 | O | PLIVA HRVATSKA d.o.o. | Teva Gyogyszergyar Zrt. | Everolimus Pliva | tbl. 30x10 mg | 388,32 | 407,73 | 11.649,47 | 12.231,94 | |
| L01EG02 131 | DS | everolimusNL420 | 10 mg | 511,64 | 537,23 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 30x2,5 mg | 127,91 | 134,31 | 3.837,33 | 4.029,20 | |
| L01EG02 132 | DS | everolimusNL420 | 10 mg | 460,48 | 483,50 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 90x2,5 mg | 115,12 | 120,88 | 10.360,78 | 10.878,82 | |
| L01EG02 133 | DS | everolimusNL420 | 10 mg | 511,64 | 537,23 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 30x5 mg | 255,82 | 268,61 | 7.674,65 | 8.058,38 | |
| L01EG02 134 | DS | everolimusNL420 | 10 mg | 460,48 | 483,50 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 90x5 mg | 230,24 | 241,75 | 20.721,56 | 21.757,64 | |
| L01EG02 135 | DS | everolimusNL420 | 10 mg | 349,48 | 366,96 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 30x10 mg | 349,48 | 366,96 | 10.484,52 | 11.008,75 | |
| L01EG02 136 | DS | everolimusNL420 | 10 mg | 314,54 | 330,26 | O | KRKA-FARMA d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Krka | tbl. 90x10 mg | 314,54 | 330,26 | 28.308,20 | 29.723,61 | |
| L01EG02 171 | DS | everolimusNL420 | 10 mg | 568,49 | 596,92 | O | Alvogen Pharma Trading Europe EOOD | Genepharm S.A., Pharmadox Healthcare Limited | Everolimus Alvogen | tbl. 30x5 mg | 284,25 | 298,46 | 8.527,39 | 8.953,76 | |
| L01EG02 172 | DS | everolimusNL420 | 10 mg | 388,32 | 407,73 | O | Alvogen Pharma Trading Europe EOOD | Genepharm S.A., Pharmadox Healthcare Limited | Everolimus Alvogen | tbl. 30x10 mg | 388,32 | 407,73 | 11.649,47 | 12.231,94 | |
| L01EG02 181 | DS | everolimusNL420 | 10 mg | 568,49 | 596,92 | O | STADA d.o.o. | Stada Arzneimittel | Everolimus STADA | tbl. 30x5 mg | 284,25 | 298,46 | 8.527,39 | 8.953,76 | |
| L01EG02 182 | DS | everolimusNL420 | 10 mg | 388,32 | 407,73 | O | STADA d.o.o. | Stada Arzneimittel | Everolimus STADA | tbl. 30x10 mg | 388,32 | 407,73 | 11.649,47 | 12.231,94 | |
| L01EG02 183 | DS | everolimusNL420 | 10 mg | 568,49 | 596,92 | O | Mylan S.A.S | Synthon Hispania S.L., Synthon BV | Everolimus Mylan | tbl. 30x5 mg | 284,25 | 298,46 | 8.527,39 | 8.953,76 | |
| L01EG02 184 | DS | everolimusNL420 | 10 mg | 388,32 | 407,73 | O | Mylan S.A.S | Synthon Hispania S.L., Synthon BV | Everolimus Mylan | tbl. 30x10 mg | 388,32 | 407,73 | 11.649,47 | 12.231,94 | |
| L01EG02 185 | DS | everolimusNL420 | 10 mg | 568,49 | 596,92 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Alpha-Medical | tbl. 30x5 mg | 284,25 | 298,46 | 8.527,39 | 8.953,76 | |
| L01EG02 186 | DS | everolimusNL420 | 10 mg | 388,32 | 407,73 | O | ALPHA-MEDICAL d.o.o. | Synthon Hispania S.L., Synthon BV | Everolimus Alpha-Medical | tbl. 30x10 mg | 388,32 | 407,73 | 11.649,47 | 12.231,94 | |
| L01EH01 161 | DS | lapatinibNL120 | 1250 mg | 581,80 | 610,89 | O | Novartis Europharm Limited Irska | Glaxo Operations UK Ltd; Glaxo Wellcome S.A., Novartis Pharmaceuticals UK Limited, Novartis Pharma GmbH | Tyverb | tbl. film obl. 70x250 mg | 116,36 | 122,18 | 8.145,20 | 8.552,46 | |
| L01EJ01 161 | DS | ruksolitinibNL453 | 30 mg | 1.518,20 | 1.594,11 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Jakavi | tbl. 56x5 mg | 253,03 | 265,69 | 14.169,87 | 14.878,36 | |
| L01EJ01 162 | DS | ruksolitinibNL453 | 30 mg | 994,82 | 1.044,56 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Jakavi | tbl. 56x15 mg | 497,41 | 522,28 | 27.855,00 | 29.247,75 | |
| L01EJ01 163 | DS | ruksolitinibNL453 | 30 mg | 746,12 | 783,42 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Jakavi | tbl. 56x20 mg | 497,41 | 522,28 | 27.855,00 | 29.247,75 | |
| L01EK01 161 | DS | aksitinibNL430 | 10 mg | 799,20 | 839,16 | O | Pfizer Europe MA EEIG | Pfizer | Inlyta | tbl. film obl. 56x1 mg | 79,92 | 83,92 | 4.475,52 | 4.699,30 | |
| L01EK01 162 | DS | aksitinibNL430 | 10 mg | 799,20 | 839,16 | O | Pfizer Europe MA EEIG | Pfizer | Inlyta | tbl. film obl. 56x5 mg | 399,60 | 419,58 | 22.377,60 | 23.496,48 | |
| L01EL01 161 | DS | ibrutinibNL502 | 420 mg | 1.350,39 | 1.417,91 | O | Janssen-Cilag International N.V. | Janssen | Imbruvica | caps. tvrda 90x140 mg | 450,13 | 472,64 | 40.511,70 | 42.537,29 | |
| L01EL01 162 | DS | ibrutinibNL471 | 420 mg | 1.349,80 | 1.417,29 | O | Janssen-Cilag International N.V. | Janssen | Imbruvica | caps. tvrda 120x140 mg | 449,93 | 472,43 | 53.992,00 | 56.691,60 | |
| L01EL01 163 | DS | ibrutinibNL527 | 420 mg | 1.349,80 | 1.417,29 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x140 mg | 449,93 | 472,43 | 12.598,13 | 13.228,04 | |
| L01EL01 164 | DS | ibrutinibNL527 | 420 mg | 1.349,80 | 1.417,29 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x280 mg | 899,87 | 944,86 | 25.196,27 | 26.456,08 | |
| L01EL01 165 | DS | ibrutinibNL527 | 420 mg | 1.349,80 | 1.417,29 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x420 mg | 1.349,80 | 1.417,29 | 37.794,40 | 39.684,12 | |
| L01EL01 166 | DS | ibrutinibNL471 | 420 mg | 1.349,80 | 1.417,29 | O | Janssen-Cilag International N.V. | Janssen-Cilag SpA | Imbruvica | tbl. film obl. 28x560 mg | 1.799,73 | 1.889,72 | 50.392,53 | 52.912,16 | |
| L01EM01 161 | DS | idelalisibNL454 | 300 mg | 1.371,48 | 1.440,05 | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Zydelig | tbl. film obl. 60x100 mg | 457,16 | 480,02 | 27.429,60 | 28.801,08 | |
| L01EM01 162 | DS | idelalisibNL454 | 300 mg | 914,32 | 960,04 | O | Gilead Sciences Ireland UC | Gilead Sciences Ireland UC | Zydelig | tbl. film obl. 60x150 mg | 457,16 | 480,02 | 27.429,60 | 28.801,08 | |
| L01EX01 101 | DS | sunitinibNL117 | 33 mg | 557,72 | 585,61 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sunitinib Pliva | caps. tvrda 28x12,5 mg | 211,26 | 221,82 | 5.915,22 | 6.210,98 | |
| L01EX01 102 | DS | sunitinibNL117 | 33 mg | 555,17 | 582,93 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sunitinib Pliva | caps. tvrda 28x25 mg | 420,59 | 441,62 | 11.776,40 | 12.365,22 | |
| L01EX01 103 | DS | sunitinibNL117 | 33 mg | 552,92 | 580,57 | O | PLIVA HRVATSKA d.o.o. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sunitinib Pliva | caps. tvrda 28x50 mg | 837,76 | 879,65 | 23.457,41 | 24.630,28 | |
| L01EX01 131 | DS | sunitinibNL117 | 33 mg | 557,73 | 585,61 | O | KRKA-FARMA d.o.o. | Krka d.d, Krka - farma d.o.o. | Sunitinib Krka | caps. tvrda 30x12,5 mg | 211,26 | 221,82 | 6.337,80 | 6.654,69 | |
| L01EX01 132 | DS | sunitinibNL117 | 33 mg | 555,18 | 582,94 | O | KRKA-FARMA d.o.o. | Krka d.d, Krka - farma d.o.o. | Sunitinib Krka | caps. tvrda 30x25 mg | 420,59 | 441,62 | 12.617,70 | 13.248,59 | |
| L01EX01 133 | DS | sunitinibNL117 | 33 mg | 552,92 | 580,57 | O | KRKA-FARMA d.o.o. | Krka d.d, Krka - farma d.o.o. | Sunitinib Krka | caps. tvrda 30x50 mg | 837,76 | 879,65 | 25.132,80 | 26.389,44 | |
| L01EX01 164 | DS | sunitinibNL117 | 33 mg | 796,74 | 836,58 | O | Pfizer Europe MA EEIG | Pfizer | Sutent | caps. tvrda 28x12,5 mg | 301,80 | 316,89 | 8.450,31 | 8.872,83 | |
| L01EX01 165 | DS | sunitinibNL117 | 33 mg | 793,10 | 832,76 | O | Pfizer Europe MA EEIG | Pfizer | Sutent | caps. tvrda 28x25 mg | 600,84 | 630,88 | 16.823,43 | 17.664,60 | |
| L01EX01 166 | DS | sunitinibNL117 | 33 mg | 789,89 | 829,39 | O | Pfizer Europe MA EEIG | Pfizer | Sutent | caps. tvrda 28x50 mg | 1.196,81 | 1.256,65 | 33.510,59 | 35.186,12 | |
| L01EX01 171 | DS | sunitinibNL117 | 33 mg | 529,83 | 556,33 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sunitinib Stada | caps. tvrda 28x12,5 mg | 200,70 | 210,73 | 5.619,46 | 5.900,43 | |
| L01EX01 172 | DS | sunitinibNL117 | 33 mg | 527,41 | 553,79 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sunitinib Stada | caps. tvrda 28x25 mg | 399,56 | 419,53 | 11.187,58 | 11.746,96 | |
| L01EX01 173 | DS | sunitinibNL117 | 33 mg | 525,28 | 551,54 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sunitinib Stada | caps. tvrda 28x50 mg | 795,88 | 835,67 | 22.284,54 | 23.398,77 | |
| L01EX01 174 | DS | sunitinibNL117 | 33 mg | 529,83 | 556,33 | O | Accord Healthcare S.L.U. | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Accord | caps. tvrda 30x12,5 mg | 200,70 | 210,73 | 6.020,85 | 6.321,89 | |
| L01EX01 175 | DS | sunitinibNL117 | 33 mg | 527,41 | 553,79 | O | Accord Healthcare S.L.U. | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Accord | caps. tvrda 30x25 mg | 399,56 | 419,53 | 11.986,69 | 12.586,02 | |
| L01EX01 176 | DS | sunitinibNL117 | 33 mg | 525,28 | 551,54 | O | Accord Healthcare S.L.U. | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Accord | caps. tvrda 30x50 mg | 795,88 | 835,67 | 23.876,29 | 25.070,10 | |
| L01EX01 177 | DS | sunitinibNL117 | 33 mg | 529,83 | 556,33 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sunitinib Sandoz | caps. tvrda 28x12,5 mg | 200,70 | 210,73 | 5.619,46 | 5.900,43 | |
| L01EX01 178 | DS | sunitinibNL117 | 33 mg | 527,41 | 553,79 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sunitinib Sandoz | caps. tvrda 28x25 mg | 399,56 | 419,53 | 11.187,58 | 11.746,96 | |
| L01EX01 179 | DS | sunitinibNL117 | 33 mg | 525,28 | 551,54 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sunitinib Sandoz | caps. tvrda 28x50 mg | 795,88 | 835,67 | 22.284,54 | 23.398,77 | |
| L01EX01 181 | DS | sunitinibNL117 | 33 mg | 503,34 | 528,51 | O | Mylan Ireland Limited | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Mylan | caps. tvrda 28x12,5 mg | 190,66 | 200,19 | 5.338,49 | 5.605,41 | |
| L01EX01 182 | DS | sunitinibNL117 | 33 mg | 501,04 | 526,10 | O | Mylan Ireland Limited | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Mylan | caps. tvrda 28x25 mg | 379,58 | 398,56 | 10.628,20 | 11.159,61 | |
| L01EX01 183 | DS | sunitinibNL117 | 33 mg | 499,01 | 523,97 | O | Mylan Ireland Limited | Remedica Ltd., Pharmacare Premium Ltd. | Sunitinib Mylan | caps. tvrda 28x50 mg | 756,08 | 793,89 | 21.170,31 | 22.228,83 | |
| L01EX01 184 | DS | sunitinibNL117 | 33 mg | 478,18 | 502,09 | O | ALPHA-MEDICAL d.o.o. | Synthon s.r.o., Synthon BV | Sunitinib Alpha-Medical | caps. tvrda 28x12,5 mg | 181,13 | 190,18 | 5.071,57 | 5.325,15 | |
| L01EX01 185 | DS | sunitinibNL117 | 33 mg | 475,99 | 499,79 | O | ALPHA-MEDICAL d.o.o. | Synthon s.r.o., Synthon BV | Sunitinib Alpha-Medical | caps. tvrda 28x25 mg | 360,60 | 378,63 | 10.096,79 | 10.601,63 | |
| L01EX01 186 | DS | sunitinibNL117 | 33 mg | 474,06 | 497,77 | O | ALPHA-MEDICAL d.o.o. | Synthon s.r.o., Synthon BV | Sunitinib Alpha-Medical | caps. tvrda 28x50 mg | 718,28 | 754,19 | 20.111,79 | 21.117,38 | |
| L01EX01 187 | DS | sunitinibNL117 | 33 mg | 478,18 | 502,09 | O | Zentiva k.s. | Remedica Ltd., Pharmacare Premium Ltd. | Zesuva | caps. tvrda 28x12,5 mg | 181,13 | 190,18 | 5.071,57 | 5.325,15 | |
| L01EX01 188 | DS | sunitinibNL117 | 33 mg | 475,99 | 499,79 | O | Zentiva k.s. | Remedica Ltd., Pharmacare Premium Ltd. | Zesuva | caps. tvrda 28x25 mg | 360,60 | 378,63 | 10.096,79 | 10.601,63 | |
| L01EX01 189 | DS | sunitinibNL117 | 33 mg | 474,06 | 497,77 | O | Zentiva k.s. | Remedica Ltd., Pharmacare Premium Ltd. | Zesuva | caps. tvrda 28x50 mg | 718,28 | 754,19 | 20.111,79 | 21.117,38 | |
| L01EX02 171 | KLDS | sorafenibNL118 | 800 mg | 586,06 | 615,36 | O | Bayer AG | Bayer HealthCare AG | Nexavar | tbl. film obl. 112x200 mg | 146,51 | 153,84 | 16.409,65 | 17.230,13 | |
| L01EX02 172 | KLDS | sorafenibNL517 | 800 mg | 586,06 | 615,36 | O | Mylan Ireland Limited | Remedica Ltd. | Sorafenib Mylan | tbl. film obl. 112x200 mg | 146,51 | 153,84 | 16.409,65 | 17.230,13 | |
| L01EX02 173 | KLDS | sorafenibNL517 | 800 mg | 586,06 | 615,36 | O | STADA d.o.o. | STADA Arzneimittel AG, STADA Arzneimittel GmbH | Sorafenib Stada | tbl. film obl. 112x200 mg | 146,51 | 153,84 | 16.409,65 | 17.230,13 | |
| L01EX02 174 | KLDS | sorafenibNL517 | 800 mg | 586,06 | 615,36 | O | Teva B.V. | Pliva Hrvatska d.o.o., Teva Operations Poland Sp. z o.o. | Sorafenib Teva | tbl. film obl. 112x200 mg | 146,51 | 153,84 | 16.409,65 | 17.230,13 | |
| L01EX02 175 | KLDS | sorafenibNL517 | 800 mg | 556,76 | 584,59 | O | Sandoz d.o.o. | Remedica Ltd., Lek Pharmaceuticals d.d. | Sorafenib Sandoz | tbl. film obl. 112x200 mg | 139,19 | 146,15 | 15.589,17 | 16.368,63 | |
| L01EX02 176 | KLDS | sorafenibNL517 | 800 mg | 556,76 | 584,59 | O | Zentiva k.s. | Remedica Ltd. | Fenesa | tbl. film obl. 112x200 mg | 139,19 | 146,15 | 15.589,17 | 16.368,63 | |
| L01EX02 177 | KLDS | sorafenibNL517 | 800 mg | 528,92 | 555,36 | O | Pharmascience International Limited | Remedica Ltd., PharOS MT Ltd. | Sorafenib Pharmascience | tbl. film obl. 112x200 mg | 132,23 | 138,84 | 14.809,71 | 15.550,20 | |
| L01EX03 161 | KLDS | pazopanibNL421 | 800 mg | 699,71 | 734,69 | O | Novartis Europharm Limited Irska | Glaxo Operations UK Ltd, Glaxo Wellcome, S.A. | Votrient | tbl. film obl. 30x200 mg | 174,93 | 183,67 | 5.247,80 | 5.510,19 | |
| L01EX03 162 | KLDS | pazopanibNL421 | 800 mg | 688,81 | 723,25 | O | Novartis Europharm Limited Irska | Glaxo Operations UK Ltd, Glaxo Wellcome, S.A. | Votrient | tbl. film obl. 30x400 mg | 344,40 | 361,62 | 10.332,10 | 10.848,71 | |
| L01EX05 161 | DS | regorafenibNL470 | 120 mg | 603,92 | 634,12 | O | Bayer AG | Bayer AG | Stivarga | tbl. film obl. 84x40 mg | 201,31 | 211,37 | 16.909,76 | 17.755,25 | |
| L01EX09 161 | KS | nintedanibNL455 | 380 mg | 800,98 | 841,03 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim Pharma GmbH | Ofev | caps. meka 60x100 mg | 210,78 | 221,32 | 12.647,00 | 13.279,35 | |
| L01EX09 162 | KS | nintedanibNL455 | 380 mg | 738,81 | 775,75 | O | Boehringer Ingelheim International GmbH | Boehringer Ingelheim Pharma GmbH | Ofev | caps. meka 60x150 mg | 291,64 | 306,22 | 17.498,20 | 18.373,11 | |
| L01EX09 171 | DS | nintedanibNL472 | 380 mg | 538,88 | 565,82 | O | Boehringer Ingelheim International GmbH | Boerhinger Ingelheim | Vargatef | caps. meka 120x100 mg | 141,81 | 148,90 | 17.017,24 | 17.868,10 | |
| L01EX09 172 | DS | nintedanibNL472 | 380 mg | 718,51 | 754,43 | O | Boehringer Ingelheim International GmbH | Boerhinger Ingelheim | Vargatef | caps. meka 60x150 mg | 283,62 | 297,80 | 17.017,24 | 17.868,10 | |
| L01EX10 171 | KL | midostaurinNL489 | 100 mg | 3.549,21 | 3.726,67 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Rydapt | caps. meka 112x25 mg | 887,30 | 931,67 | 99.377,85 | 104.346,74 | |
| L01FA01 061 | DS | rituksimabNL518 | P | Roche Registration GmbH | Roche | Mabthera | boč. 2x100 mg/10 ml | 1.520,08 | 1.596,08 | 3.040,16 | 3.192,17 | ||||
| L01FA01 062 | DS | rituksimabNL518 | P | Roche Registration GmbH | Roche | Mabthera | boč. 1x500 mg/50 ml | 7.464,09 | 7.837,29 | 7.464,09 | 7.837,29 | ||||
| L01FA01 063 | DS | rituksimabNL429 | P | Roche Registration GmbH | Roche | Mabthera | otop. za supkut. inj., boč. 1x1400 mg | 10.504,25 | 11.029,46 | 10.504,25 | 11.029,46 | ||||
| L01FA01 071 | DS | rituksimabNL518 | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd. | Truxima | konc. za otop. za inf., boč. stakl. 1x500 mg/50 ml | 7.464,09 | 7.837,29 | 7.464,09 | 7.837,29 | ||||
| L01FA01 072 | DS | rituksimabNL518 | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd. | Truxima | konc. za otop. za inf., boč. stakl. 2x100 mg/10 ml | 1.520,08 | 1.596,08 | 3.040,16 | 3.192,17 | ||||
| L01FA01 081 | DS | rituksimabNL518 | P | Sandoz GmbH | Sandoz GmbH | Rixathon | konc. za otop. za inf., boč. stakl. 2x100 mg/10 ml | 1.368,07 | 1.436,47 | 2.736,14 | 2.872,95 | ||||
| L01FA01 082 | DS | rituksimabNL518 | P | Sandoz GmbH | Sandoz GmbH | Rixathon | konc. za otop. za inf., boč. stakl. 1x500 mg/50 ml | 6.717,68 | 7.053,56 | 6.717,68 | 7.053,56 | ||||
| L01FA01 083 | DS | rituksimabNL111 | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Ruxience | konc. za otop. za inf., boč. stakl. 1x100 mg/10 ml | 1.299,67 | 1.364,65 | 1.299,67 | 1.364,65 | ||||
| L01FA01 084 | DS | rituksimabNL111 | P | Pfizer Europe MA EEIG | Pfizer Manufacturing Belgium NV | Ruxience | konc. za otop. za inf., boč. stakl. 1x500 mg/50 ml | 6.381,80 | 6.700,89 | 6.381,80 | 6.700,89 | ||||
| L01FA03 061 | DS | obinutuzumabNL451 | P | Roche Registration GmbH | Roche Pharma AG | Gazyvaro | konc. za otop. za inf., boč. stakl. 1x1000 mg/40 ml | 24.898,97 | 26.143,92 | 24.898,97 | 26.143,92 | ||||
| L01FC01 071 | KS | daratumumabNL492 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V | Darzalex | konc. za otop. za inf., boč. stakl. 1x100 mg/5 ml | 3.221,44 | 3.382,51 | 3.221,44 | 3.382,51 | ||||
| L01FC01 072 | KS | daratumumabNL492 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V | Darzalex | konc. za otop. za inf., boč. stakl. 1x400 mg/20 ml | 12.649,05 | 13.281,50 | 12.649,05 | 13.281,50 | ||||
| L01FC01 073 | KS | daratumumabNL492 | P | Janssen-Cilag International N.V. | Janssen Biologics B.V | Darzalex | otop. za supkut. inj., boč. 1x1800 mg/15 ml | 38.207,30 | 40.117,67 | 38.207,30 | 40.117,67 | ||||
| L01FD01 061 | DS | trastuzumab NL112 | P | Roche Registration GmbH | Roche | Herceptin | boč. 1x150 mg | 2.935,41 | 3.082,18 | 2.935,41 | 3.082,18 | ||||
| L01FD01 062 | DS | trastuzumab NL487 | P | Roche Registration GmbH | Roche | Herceptin | otop. za supkut. inj., boč. 1x600 mg/5 ml | 8.806,23 | 9.246,54 | 8.806,23 | 9.246,54 | ||||
| L01FD01 071 | DS | trastuzumab NL112 | P | Celltrion Healthcare Hungary Kft. | Biotec Services International Ltd | Herzuma | boč. 1x150 mg | 2.935,41 | 3.082,18 | 2.935,41 | 3.082,18 | ||||
| L01FD01 072 | DS | trastuzumab NL112 | P | Mylan S.A.S | McDermott Laboratories Limited T/A Mylan Dublin Biologics | Ogivri | boč. 1x150 mg | 2.788,64 | 2.928,07 | 2.788,64 | 2.928,07 | ||||
| L01FD01 081 | DS | trastuzumab NL112 | P | Amgen Europe B.V. | Amgen Europe B.V. | Kanjinti | boč. 1x150 mg | 2.935,41 | 3.082,18 | 2.935,41 | 3.082,18 | ||||
| L01FD01 082 | DS | trastuzumab NL112 | P | Amgen Europe B.V. | Amgen Europe B.V. | Kanjinti | boč. 1x420 mg | 8.219,15 | 8.630,11 | 8.219,15 | 8.630,11 | ||||
| L01FD01 083 | DS | trastuzumab NL112 | P | Pfizer Europe MA EEIG | Wyeth Pharmaceuticals, Pfizer Manufacturing Belgium NV | Trazimera | boč. 1x150 mg | 2.935,41 | 3.082,18 | 2.935,41 | 3.082,18 | ||||
| L01FD01 084 | DS | trastuzumab NL112 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Zercepac | boč. 1x150 mg | 2.649,21 | 2.781,67 | 2.649,21 | 2.781,67 | ||||
| L01FD01 085 | DS | trastuzumab NL112 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Zercepac | boč. 1x60 mg | 1.006,70 | 1.057,04 | 1.006,70 | 1.057,04 | ||||
| L01FD01 086 | DS | trastuzumab NL112 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Accord Healthcare Polska Sp. z o.o. | Zercepac | boč. 1x420 mg | 7.311,82 | 7.677,41 | 7.311,82 | 7.677,41 | ||||
| L01FD02 061 | DS | pertuzumabNL443 | P | Roche Registration GmbH | Roche Pharma AG | Perjeta | konc. za otop. za inf., boč. stakl. 1x420 mg | 19.988,62 | 20.988,05 | 19.988,62 | 20.988,05 | ||||
| L01FD03 061 | DS | trastuzumab emtanzinNL450 | P | Roche Registration GmbH | Roche Pharma AG | Kadcyla | praš. za konc. za otop. za inf., boč. stakl. 1x100 mg | 12.739,00 | 13.375,95 | 12.739,00 | 13.375,95 | ||||
| L01FD03 062 | DS | trastuzumab emtanzinNL450 | P | Roche Registration GmbH | Roche Pharma AG | Kadcyla | praš. za konc. za otop. za inf., boč. stakl. 1x160 mg | 20.376,00 | 21.394,80 | 20.376,00 | 21.394,80 | ||||
| L01FE01 061 | DS | cetuksimabNL113 | P | Merck Europe B.V. | Merck Healthcare KGaA | Erbitux | otop. za inf., boč. 1x20 ml (5 mg/ml) | 1.389,84 | 1.459,33 | 1.389,84 | 1.459,33 | ||||
| L01FE02 061 | DS | panitumumabNL431 | P | Amgen Europe B.V. | Amgen Europe B.V. | Vectibix | konc. za otop. za inf., boč. 1x5 ml (20 mg/ml) | 2.763,47 | 2.901,64 | 2.763,47 | 2.901,64 | ||||
| L01FF01 061 | KS | nivolumabNL467 | P | Bristol-Myers Squibb Pharma EEIG | Bristol - Myers Squibb S.r.l. | Opdivo | konc. za otop. za inf., boč. stakl. 1x4 ml (10 mg/ml) | 3.953,05 | 4.150,70 | 3.953,05 | 4.150,70 | ||||
| L01FF01 062 | KS | nivolumabNL467 | P | Bristol-Myers Squibb Pharma EEIG | Bristol - Myers Squibb S.r.l. | Opdivo | konc. za otop. za inf., boč. stakl. 1x10 ml (10 mg/ml) | 9.759,60 | 10.247,58 | 9.759,60 | 10.247,58 | ||||
| L01FF01 063 | KS | nivolumabNL467 | P | Bristol-Myers Squibb Pharma EEIG | Bristol - Myers Squibb S.r.l. | Opdivo | konc. za otop. za inf., boč. stakl. 1x24 ml (10 mg/ml) | 23.472,25 | 24.645,86 | 23.472,25 | 24.645,86 | ||||
| L01FF02 062 | KS | pembrolizumabNL452 | P | Merck Sharp & Dohme B.V. | Schering - Plough Labo NV | Keytruda | konc. za otop. za inf., boč. stakl. 1x100 mg/4 ml (25 mg/ml) | 22.683,16 | 23.817,32 | 22.683,16 | 23.817,32 | ||||
| L01FF03 061 | KS | durvalumabNL515 | P | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | Imfinzi | konc. za otop. za inf., boč. stakl. 1x120 mg/2,4 ml (50mg/ml) | 4.927,37 | 5.173,74 | 4.927,37 | 5.173,74 | ||||
| L01FF03 062 | KS | durvalumabNL515 | P | AstraZeneca AB | AstraZeneca Pharmaceuticals LP | Imfinzi | konc. za otop. za inf., boč. stakl. 1x500 mg/10 ml (50mg/ml) | 20.224,46 | 21.235,68 | 20.224,46 | 21.235,68 | ||||
| L01FF04 061 | KL | avelumabNL519 | P | Merck Europe B.V. | Merck Serono S.p.A. | Bavencio | konc. za otop. za inf. 10 ml, boč. stakl. 1x20 mg/ml | 6.947,17 | 7.294,53 | 6.947,17 | 7.294,53 | ||||
| L01FF05 071 | KS | atezolizumabNL529 | P | Roche Registration GmbH | Roche Pharma AG | Tecentriq | konc. otop. za inf., boč. 1x1200 mg/20 ml | 30.555,70 | 32.083,49 | 30.555,70 | 32.083,49 | ||||
| L01FF05 072 | KS | atezolizumabNL529 | P | Roche Registration GmbH | Roche Pharma AG | Tecentriq | konc. otop. za inf., boč. 1x840 mg/14 ml | 21.388,99 | 22.458,44 | 21.388,99 | 22.458,44 | ||||
| L01FG01 061 | DS | bevacizumab NL128 | P | Roche Registration GmbH | Roche | Avastin | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.954,83 | 2.052,57 | 1.954,83 | 2.052,57 | ||||
| L01FG01 062 | DS | bevacizumabNL128 | P | Roche Registration GmbH | Roche | Avastin | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 7.274,05 | 7.637,75 | 7.274,05 | 7.637,75 | ||||
| L01FG01 071 | DS | bevacizumab NL128 | P | Amgen Technology (Ireland) UC | Amgen Technology (Ireland) UC | Mvasi | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.835,66 | 1.927,44 | 1.835,66 | 1.927,44 | ||||
| L01FG01 072 | DS | bevacizumab NL128 | P | Amgen Technology (Ireland) UC | Amgen Technology (Ireland) UC | Mvasi | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 7.015,60 | 7.366,38 | 7.015,60 | 7.366,38 | ||||
| L01FG01 073 | DS | bevacizumab NL128 | P | Mabxience Research S.L. | GH Genhelix S.A. | Alymsys | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.743,88 | 1.831,07 | 1.743,88 | 1.831,07 | ||||
| L01FG01 074 | DS | bevacizumab NL128 | P | Mabxience Research S.L. | GH Genhelix S.A. | Alymsys | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 6.664,82 | 6.998,06 | 6.664,82 | 6.998,06 | ||||
| L01FG01 075 | DS | bevacizumab NL128 | P | STADA Arzneimittel AG | GH GENHELIX S.A. | Oyavas | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.743,88 | 1.831,07 | 1.743,88 | 1.831,07 | ||||
| L01FG01 076 | DS | bevacizumab NL128 | P | STADA Arzneimittel AG | GH GENHELIX S.A. | Oyavas | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 6.664,82 | 6.998,06 | 6.664,82 | 6.998,06 | ||||
| L01FG01 077 | DS | bevacizumab NL128 | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Limited t/a Mylan Dublin Biologics, Mylan Germany GmbH | Abevmy | konc. otop. za inf., boč. 1x100 mg/4 ml (25 mg/ml) | 1.656,69 | 1.739,52 | 1.656,69 | 1.739,52 | ||||
| L01FG01 078 | DS | bevacizumab NL128 | P | Mylan IRE Healthcare Ltd | McDermott Laboratories Limited t/a Mylan Dublin Biologics, Mylan Germany GmbH | Abevmy | konc. otop. za inf., boč. 1x400 mg/16 ml (25 mg/ml) | 6.331,58 | 6.648,16 | 6.331,58 | 6.648,16 | ||||
| L01FG02 061 | KS | ramucirumabNL469 | P | Eli Lilly Nederland B.V. | Lilly, S.A. | Cyramza | konc. za otop. za inf., boč. stakl. 2x10 ml (10 mg/ml) | 3.822,69 | 4.013,82 | 7.645,38 | 8.027,65 | ||||
| L01FX02 061 | KS | gemtuzumab ozogamicinNL525 | P | Pfizer Europe MA EEIG | Pfizer Ireland Pharmaceuticals | Mylotarg | praš. za konc. za otop. za inf., boč. stakl. 1x5 mg | 57.699,86 | 60.584,85 | 57.699,86 | 60.584,85 | ||||
| L01FX04 061 | KS | ipilimumabNL523 | P | Bristol-Myers Squibb Pharma EEIG | CATALENT ANAGNI S.R.L., Swords Laboratories T/A Bristol-Myers Squibb Cruiserath Biologics | Yervoy | konc. za otop. za inf., boč. stakl. 1x10 ml (5 mg/ml) | 26.558,64 | 27.886,57 | 26.558,64 | 27.886,57 | ||||
| L01FX05 061 | DS | brentuksimab vedotinNL442 | P | Takeda Pharma A/S | Takeda Italia S.p.A. | Adcetris | praš. za konc. za otop. za inf., boč. stakl. 1x50 mg | 22.143,91 | 23.251,11 | 22.143,91 | 23.251,11 | ||||
| L01FX06 061 | KL | dinutuksimab betaNL508 | P | EUSA Pharma (Netherlands) B.V. | Millmount Healthcare Ltd | Qarziba | konc. za otop. za inf., boč. stakl. 1x20 mg (4,5 mg/ml) | 69.464,16 | 72.937,37 | 69.464,16 | 72.937,37 | ||||
| L01EM03 171 | DS | alpelisibNL531 | 300 mg | 1.045,34 | 1.097,61 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Piqray | tbl. film obl. 28x50 mg + 28x200 mg | 435,56 | 457,34 | 24.391,36 | 25.610,93 | |
| L01EM03 172 | DS | alpelisibNL531 | 300 mg | 871,12 | 914,68 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Piqray | tbl. film obl. 56x150 mg | 435,56 | 457,34 | 24.391,36 | 25.610,93 | |
| L01EM03 173 | DS | alpelisibNL531 | 300 mg | 1.306,68 | 1.372,01 | O | Novartis Europharm Limited Irska | Novartis Pharma GmbH | Piqray | tbl. film obl. 28x200 mg | 871,12 | 914,68 | 24.391,36 | 25.610,93 | |
| L02BB06 161 | DS | darolutamidNL514 | 120 mg | 80,64 | 84,67 | O | Bayer AG | Orion Corporation, Orion Pharma | Nubeqa | tbl. film obl. 112x300 mg | 201,59 | 211,67 | 22.578,08 | 23.706,98 | |
| L04AA43 061 | KL | ravulizumab NL524 | 58.9 mg | 6.372,84 | 6.691,48 | P | Alexion Europe SAS | Alexion Pharma International Operations Unlimited Company | Ultomiris | konc. za otop. za inf., boč. stakl. 1x300 mg (30 ml, 10 mg/ml) | 32.459,30 | 34.082,27 | 32.459,30 | 34.082,27 | |
| L04AA44 161 | upadacitinibNL512 | 15 mg | 180,25 | 189,27 | O | AbbVie Deutschland GmbH & Co. KG | AbbVie S.r.l. | Rinvoq | tbl. s prod. oslob. 28x15 mg | 180,25 | 189,27 | 5.047,08 | 5.299,43 | RSRL107 | |
| N02CC01 162 | sumatriptan | 50 mg | 9,36 | 9,82 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Imigran | tbl. 2x50 mg | 9,36 | 9,82 | 18,71 | 19,65 | RSRN03 | |
| N03AX09 175 | lamotrigin | 0,3 g | 4,31 | 4,52 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. 56x25 mg | 0,36 | 0,38 | 20,11 | 21,12 | RSRN22 | |
| N03AX09 176 | lamotrigin | 0,3 g | 6,70 | 7,03 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. 56x50 mg | 1,12 | 1,17 | 62,50 | 65,63 | RSRN22 | |
| N03AX09 177 | lamotrigin | 0,3 g | 5,85 | 6,14 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. 56x100 mg | 1,95 | 2,05 | 109,20 | 114,66 | RSRN22 | |
| N03AX09 180 | lamotrigin | 0,3 g | 55,20 | 57,96 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Lamictal | tbl. za žvak./oral. susp. 60x5 mg | 0,92 | 0,97 | 55,20 | 57,96 | RSRN22 | |
| N04BC04 176 | ropinirol | 6 mg | 9,66 | 10,14 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A., Glaxo Wellcome GmbH&Co.KG, Glaxo Wellcome S.A., SmithKline Beecham Plc | Requip Modutab | tbl. s prod. oslob. 28x2 mg | 2,29 | 2,40 | 64,12 | 67,33 | R | |
| N04BC04 177 | ropinirol | 6 mg | 9,15 | 9,60 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A., Glaxo Wellcome GmbH&Co.KG, Glaxo Wellcome S.A., SmithKline Beecham Plc | Requip Modutab | tbl. s prod. oslob. 28x4 mg | 4,48 | 4,70 | 125,31 | 131,58 | R | |
| N04BC04 178 | ropinirol | 6 mg | 8,09 | 8,50 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A., Glaxo Wellcome GmbH&Co.KG, Glaxo Wellcome S.A., SmithKline Beecham Plc | Requip Modutab | tbl. s prod. oslob. 28x8 mg | 8,51 | 8,94 | 238,28 | 250,19 | R | |
| N06AB05 111 | paroksetin | 20 mg | 0,64 | 0,68 | O | GlaxoSmithKline Trading Services Limited | GlaxoSmithKline Pharmaceuticals S.A. | Seroxat | tbl. 30x20 mg | 0,64 | 0,68 | 19,29 | 20,25 | R | |
| N06AX27 761 | DS | esketaminNN507 | 8 mg | 492,35 | 516,97 | N | Janssen-Cilag International N.V. | Janssen Pharmaceutica NV | Spravato | sprej za nos, 1x28 mg | 1.723,22 | 1.809,38 | 1.723,22 | 1.809,38 | |
| R03AC12 763 | salmeterol | 0,1 mg | 4,60 | 4,83 | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production | Serevent inhaler | stlač. inhalat, susp., 120x25 mcg | 1,15 | 1,21 | 138,00 | 144,90 | R | |
| R03AK06 361 | salmeterol + flutikazon | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Seretide 100 Diskus | praš. za inhal. 60x(50+100 mcg)/doza | 1,86 | 1,96 | 111,72 | 117,31 | RRR02 | ||||
| R03AK06 362 | salmeterol + flutikazon | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Seretide 250 Diskus | praš. za inhal. 60x(50+250 mcg)/doza | 2,42 | 2,54 | 144,90 | 152,15 | RRR02 | ||||
| R03AK06 363 | salmeterol + flutikazon | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, Glaxo Operations UK Ltd. | Seretide 500 Diskus | praš. za inhal. 60x(50+500 mcg)/doza | 3,18 | 3,34 | 190,68 | 200,21 | RRR03 | ||||
| R03BA05 773 | flutikazon | 0,6 mg | 6,12 | 6,43 | I | GlaxoSmithKline Trading Services Limited | Glaxo Wellcome Production, GlaxoWellcome S.A. | Flixotide inhaler | stlač. inhalat, susp. 120x50 mcg | 0,51 | 0,54 | 61,20 | 64,26 | RRR07 |
«.
Dodaju se nove šifre anatomsko-terapijsko-kemijske (ATK) klasifikacije lijekova Svjetske zdravstvene organizacije, sa sljedećim podacima:
»
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena za DDD | Cijena za DDD (s PDV-om) | Način primjene | Nositelj odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena jed. oblika | Cijena jed. oblika (s PDV-om) | Cijena orig. pakiranja | Cijena orig. pakiranja (s PDV-om) | R/RS |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. | 15. | 16. |
| B05AA01 964 | DS | ljudski albumin 20%NB502 | P | Jana Pharm d.o.o. | Octapharma | Albunorm 20% (HR) | otop. za inf., boč. stakl. 1x100 ml | 326,87 | 343,21 | 326,87 | 343,21 | ||||
| J01DD01 061 | DS | cefotaksimNJ101 | 4 g | 87,44 | 91,81 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefotaksim AptaPharma | praš. za otop. za inj/inf., boč. 10x1 g | 21,86 | 22,95 | 218,60 | 229,53 | |
| J01DD01 062 | DS | cefotaksimNJ101 | 4 g | 87,28 | 91,65 | P | Apta Medica International d.o.o. | ACS Dobfar S.p.A. | Cefotaksim AptaPharma | praš. za otop. za inj/inf., boč. 10x2 g | 43,64 | 45,82 | 436,41 | 458,23 | |
| J01DH02 085 | DS | meropenemNJ101 | 3 g | 250,26 | 262,77 | P | Ligula Pharma d.o.o. | Venus Pharma GmbH | Meropenem Ligula Pharma | praš. za otop. za inj. ili inf., boč. 10x500 mg | 41,71 | 43,80 | 417,10 | 437,96 | |
| J01DH02 086 | DS | meropenemNJ101 | 3 g | 228,42 | 239,84 | P | Ligula Pharma d.o.o. | Venus Pharma GmbH | Meropenem Ligula Pharma | praš. za otop. za inj. ili inf., boč. 10x1000 mg | 76,14 | 79,95 | 761,40 | 799,47 | |
| J01XA01 083 | DS | vankomicinNJ101 | 2 g | 91,20 | 95,76 | P | Apta Medica International d.o.o. | Laboratorio Reig Jofre S.A. | Vankomicin AptaPharma | praš. za otop. za inf., boč. 10x500 mg | 22,80 | 23,94 | 228,00 | 239,40 | |
| J01XA01 084 | DS | vankomicinNJ101 | 2 g | 84,66 | 88,90 | P | Apta Medica International d.o.o. | Laboratorio Reig Jofre S.A. | Vankomicin AptaPharma | praš. za otop. za inf., boč. 10x1000 mg | 42,33 | 44,45 | 423,32 | 444,49 | |
| L01BA04 045 | DS | pemetreksedNL102 | P | Accord Healthcare S.L.U. | Accord Healthcare Limited, Wessling Hungary Kft | Pemetrexed Accord | konc. za otop. za inf., boč. 1x1000 mg | 5.828,35 | 6.119,77 | 5.828,35 | 6.119,77 | ||||
| L01XK04 161 | DS | talazoparibNL530 | O | Pfizer Europe MA EEIG | Excella GmbH & Co. KG | Talzenna | caps. 30x0,25 mg | 450,87 | 473,41 | 13.526,10 | 14.202,41 | ||||
| L01XK04 162 | DS | talazoparibNL530 | O | Pfizer Europe MA EEIG | Excella GmbH & Co. KG | Talzenna | caps. 30x1 mg | 1.341,08 | 1.408,13 | 40.232,40 | 42.244,02 | ||||
| V06DX03 492 | namirnice za enteralnu primjenu | O | G-M Pharma Zagreb d.o.o. | Nutricia | Nutridrink Compact Protein | boca 4x125 ml | 16,25 | 17,06 | 65,00 | 68,25 | RSVS04a |
«.
Brišu se šifre anatomsko-terapijsko-kemijske (ATK) klasifikacije lijekova Svjetske zdravstvene organizacije, sa sljedećim podacima:
»
| Šifra ATK | Oznaka | Nezaštićeno ime lijeka | DDD i jed. mj. | Cijena za DDD | Cijena za DDD (s PDV-om) | Način primjene | Nositelj odobrenja | Proizvođač | Zaštićeno ime lijeka | Oblik, jačina i pakiranje lijeka | Cijena jed. oblika | Cijena jed. oblika (s PDV-om) | Cijena orig. pakiranja | Cijena orig. pakiranja (s PDV-om) | R/RS |
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. | 12. | 13. | 14. | 15. | 16. |
| A04AA05 081 | DS | palonosetronNA402 | 0,25 mg | 238,59 | 250,52 | P | Alvogen Pharma Trading Europe EOOD | Haupt Pharma Wolfrathausen GmbH | Palonozetron Alvogen | otop. za inj., boč. 1x250 mcg/5 ml | 238,59 | 250,52 | 238,59 | 250,52 | |
| C07AB07 143 | bisoprolol | 10 mg | 0,83 | 0,87 | O | Jadran - Galenski Laboratorij d.d. | JGL d.d. | Lybrol | tbl. 30x3,75 mg | 0,31 | 0,33 | 9,32 | 9,79 | R | |
| C08CA05 131 | nifedipin srednje dugodjelujući | 30 mg | 0,71 | 0,74 | O | KRKA-FARMA d.o.o. | Krka d.d. | Cordipin R | tbl. 30x20 mg | 0,47 | 0,49 | 14,11 | 14,82 | R | |
| J05AP01 171 | DS | ribavirin | 1 g | 81,48 | 85,56 | O | Roche d.o.o. | Roche | Copegus | tbl. film obl. 42x200 mg | 16,30 | 17,11 | 684,46 | 718,68 | |
| L01BA01 005 | DS | metotreksat | P | Zentiva k.s. | Pliva Hrvatska d.o.o. | Metotreksat Zentiva | otop. za inj., boč. stakl. 1x5 mg/2 ml (2,5 mg/1 ml) | 12,79 | 13,43 | 12,79 | 13,43 | ||||
| L01EA01 172 | DS | imatinibNL115 | O | Novartis Europharm Limited Irska | Novartis Pharma | Glivec | tbl. film obl. 60x100 mg | 54,57 | 57,30 | 3.274,20 | 3.437,91 | ||||
| L02AB01 171 | megestrol-acetat | 0,16 g | 8,11 | 8,51 | O | PharmaSwiss Česka republika s.r.o | Polfarmex S.A. | Megoxi | susp. za oral. primj. 1x240 ml (40 mg/ml) | 486,50 | 510,83 | 486,50 | 510,83 | RSRL22 | |
| N05AX08 113 | risperidon | 5 mg | 4,92 | 5,16 | O | Belupo d.d. | Belupo | Prospera | tbl. film obl. 60x3 mg | 2,95 | 3,10 | 177,00 | 185,85 | RSRN06 | |
| N05AX08 114 | risperidon | 5 mg | 6,57 | 6,90 | O | Belupo d.d. | Belupo | Prospera | tbl. film obl. 60x4 mg | 5,26 | 5,52 | 315,40 | 331,17 | RSRN06 |
«.
Dodaje se nova indikacija pod oznakom: »NL530« koja glasi:
»NL530: Monoterapija za liječenje odraslih bolesnika sa zametnim mutacijama gena BRCA1 i BRCA2 koji boluju od lokalno uznapredovalog ili metastatskog trostruko-negativnog raka dojke. Bolesnici su prethodno trebali biti liječeni antraciklinom i/ili taksanom u (neo)adjuvantnom, lokalno uznapredovalom ili metastatskom okruženju osim ako ta liječenja nisu bila prikladna za bolesnike. Nastavak liječenja moguć je isključivo kod pozitivnog tumorskog odgovora na provedeno liječenje (kompletna remisija, parcijalna remisija ili stabilna bolest) uz obveznu prvu procjenu terapijskog učinka liječenja nakon 3 ciklusa liječenja. Svaka sljedeća procjena se radi nakon provedenih 3 ciklusa liječenja. Liječenje odobrava Bolničko povjerenstvo za lijekova na prijedlog internističkog onkologa ili specijalista radioterapije i onkologije.«.
Članak 2.
Ova Odluka objavljuje se u »Narodnim novinama«, a stupa na snagu 1. veljače 2022. godine.
Klasa: 025-04/22-01/02
Urbroj: 338-01-01-22-01
Zagreb, 11. siječnja 2022.
Predsjednik
Upravnog vijeća Hrvatskog zavoda
za zdravstveno osiguranje
prof. dr. sc. Drago Prgomet, dr. med. spec., v. r.